No more transplants for relapsed or refractory HL in the future?

The standard treatment approach for relapsed or refractory (RR) classical Hodgkin’s lymphoma (HL) after failure of first-line treatment is second-line therapy with the aim of achieving complete remission (CR), followed by consolidation with high-dose therapy and autologous hematopoietic cell transplantation (HDT/AHCT). Researchers investigated whether transplantation can be dispensed with in the future under certain conditions.